Hot genomic studies discovered that Fms-like tyrosine kinase 3 (FLT3) was overexpressed in AML leukemic blasts, and the FLT3 gene mutation was highly common in nearly 30% of AML-investigated patients. Here, FLT3 is linked to acute myeloid leukemia.